Analysts and consensus

Analyst Coverage

Bank	Analyst	Email	Phone	Location
SEB	Christopher Uhde	[email protected]	+46 876 385 53	Stockholm
ABG Sundal Collier	Alexander Krämer	[email protected]	+46 856 628 691	Stockholm
Redeye	Johan Unnerus	[email protected]	+46 724 023 385	Stockholm
Van Lanschot Kempen	Suzanne van Voorthuizen	[email protected]	+31 6 29 71 3490	Amsterdam
Carnegie	Erik Hultgård	[email protected]	+46 (0)8 5886 9237	Stockholm
Intron Health Research	Naresh Chouhan	[email protected]	+44 7939 224 322	London
Ökonomisk Ugebrev	Lars Hatholt	[email protected]	+45 22 23 78 15	Copenhagen
H.C. Wainwright & Co.	Douglas Tsao	[email protected]	+1 212 916 3968	New York City
William Blair	Matt Phipps	[email protected]	+1 312 364 8602	Chicago

Analyst Consensus

Company collected consensus updated on a quarterly basis after the publication of the latest financial report. Latest update 12-04-2024.

			Patient uptake, EU				Product Sales estimates, SEKm				Revenue estimates, SEKm				EBIT, SEKm				Operating Cash Flow, SEKm				Cash position, SEKm
Consensus model	Price target, SEK	WACC	Q1'24e	FY'24e	FY'25e	FY'26e	Q1'24e	FY'24e	FY'25e	FY'26e	Q1'24e	FY'24e	FY'25e	FY'26e	Q1'24e	FY'24e	FY'25e	FY'26e	Q1'24e	FY'24e	FY'25e	FY'26e	Q1'24e	FY'24e	FY'25e	FY'26e
Average	92	12%	16	72	107	171	48	189	280	485	54	235	330	611	-163	-623	-522	-376	-167	-636	-511	-496	570	436	701	560
Median	92	12%	16	72	105	168	48	196	298	489	54	240	315	662	-166	-636	-525	-366	-161	-615	-490	-430	569	223	456	655
High	173	15%	17	89	146	223	48	220	337	712	54	283	455	887	-139	-537	-372	-95	-161	-512	-348	-376	591	1 077	2 895	1 807
Low	50	10%	14	58	82	126	48	130	156	261	54	173	221	314	-175	-694	-749	-772	-179	-828	-674	-772	550	62	-468	-888
Number of contributions	8	8	4	6	6	5	9	8	8	7	9	8	8	7	5	8	8	7	3	6	6	5	3	7	6	5

Download consensus

Recommendation
Buy	8
Hold	1
Sell	0

^{This is a company-collected consensus prepared with consolidated estimates submitted from research analysts covering the Hansa Biopharma stock. The consensus provided is based on a collection of estimates done on a quarterly basis.}^{Any opinions, forecasts, estimates, projections or predictions regarding Hansa Biopharma’s performance made by the analysts (and, therefore, the consensus estimate numbers) are theirs alone and do not represent the opinions, forecasts, estimates, projections or predictions of Hansa Biopharma or its management.}^{Hansa Biopharma does not by providing these estimates imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations made or provided by such analysts. Hansa Biopharma assumes no liability for the accuracy of such estimates and undertakes no obligation to update or revise such estimates.}